Generation of safe and therapeutically effective human induced pluripotent stem cell‐derived hepatocyte‐like cells for regenerative medicine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Hepatocyte‐like cells (HLCs) differentiated from human induced pluripotent stem (iPS) cells are expected to be applied for regenerative medicine. In this study, we attempted to generate safe and therapeutically effective human iPS‐HLCs for hepatocyte transplantation. First, human iPS‐HLCs were generated from a human leukocyte antigen‐homozygous donor on the assumption that the allogenic transplantation might be carried out. Highly efficient hepatocyte differentiation was performed under a feeder‐free condition using human recombinant laminin 111, laminin 511, and type IV collagen. The percentage of asialoglycoprotein receptor 1‐positive cells was greater than 80%, while the percentage of residual undifferentiated cells was approximately 0.003%. In addition, no teratoma formation was observed even at 16 weeks after human iPS‐HLC transplantation. Furthermore, harmful genetic somatic single‐nucleotide substitutions were not observed during the hepatocyte differentiation process. We also developed a cryopreservation protocol for hepatoblast‐like cells without negatively affecting their hepatocyte differentiation potential by programming the freezing temperature. To evaluate the therapeutic potential of human iPS‐HLCs, these cells (1 × 10 6 cells/mouse) were intrasplenically transplanted into acute liver injury mice treated with 3 mL/kg CCl 4 only once and chronic liver injury mice treated with 0.6 mL/kg CCl 4 twice weekly for 8 weeks. By human iPS‐HLC transplantation, the survival rate of the acute liver injury mice was significantly increased and the liver fibrosis level of chronic liver injury mice was significantly decreased. Conclusion: We were able to generate safe and therapeutically effective human iPS‐HLCs for hepatocyte transplantation. (Hepatology Communications 2017;1:1058–1069)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 1×
“Several groups, including us, have developed hepatocyte differentiation technologies from human iPS cells and have demonstrated the therapeutic potential of human iPS-HLCs against liver failure by using mice models of liver failure.((4-7)) However, the clinical application of human iPS-HLCs has not been realized becau…”
BackgroundHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Yamanaka, S. (2009) · Cell · doi:10.1016/j.cell.2009.03.034 · Cited by 659 · cited 1×
“The major concerns of the clinical application of iPS cell derivatives (including hepatocytes) are teratoma formation, oncogenesis, and immune rejection.((8)) To address these concerns, measuring the rate of residual undifferentiated cells and evaluating the risk of teratoma formation by transplanting iPS cell derivat…”
BackgroundMiyazaki, T., Futaki, S., Suemori, H., Taniguchi, Y., Yamada, M., Kawasaki, M., Hayashi, M., Kumagai, H., Nakatsuji, N., Sekiguchi, K., et al. (2012) · Nature Communications · doi:10.1038/ncomms2231 · Cited by 368 · cited 16×
“In this study, we showed that the percentage of residual undifferentiated cells could be reduced to about 0.003% by performing HBC purification using LN511-E8.”
BackgroundMethodInfluentialSelf-citation
Cited by
Engineering Liver Microtissues for Disease Modeling and Regenerative Medicine
Huang, D. (., Gibeley, S. B., Xu, C., Xiao, Y., Celik, O., Ginsberg, H. N., & Leong, K. W. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909553 · Cited by 65
Generation of multi-cellular human liver organoids from pluripotent stem cells
(2020) · Methods in Cell Biology · doi:10.1016/bs.mcb.2020.03.009 · Cited by 55
Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview
Pinheiro, D., Dias, I., Ribeiro Silva, K., Stumbo, A. C., Thole, A., Cortez, E., de Carvalho, L., Weiskirchen, R., & Carvalho, S. (2019) · Cells · doi:10.3390/cells8111339 · Cited by 46
Macrophages as a Cell-Based Therapy for Liver Disease
Starkey Lewis, P. J., Moroni, F., & Forbes, S. J. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1688502 · Cited by 36
Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source
Chen, F., Wang, H., & Xiao, J. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.0022n · Cited by 8
Metadata
- Authors
- Takayama, K., Akita, N., Mimura, N., Akahira, R., Taniguchi, Y., Ikeda, M., Sakurai, F., Ohara, O., Morio, T., Sekiguchi, K., & Mizuguchi, H.
- Venue
- Hepatology Communications
- Published
- 2017-10-12
- Volume
- 1
- Issue
- 10
- Pages
- 1058-1069
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2763196526
- Cited by
- 80
- References
- 4
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.